<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Epstein-Barr virus (EBV) is involved in the <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> of several human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> such as nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> (NPC) and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Given the consistent role of EBV in transformation and maintenance of malignant phenotype, antiviral strategies provide an attractive approach to target EBV-expressing cells </plain></SENT>
<SENT sid="2" pm="."><plain>In that aim, we have tested the Cidofovir, which is an acyclic <z:chebi fb="0" ids="33838">nucleoside</z:chebi> <z:chebi fb="0" ids="16215,26066">phosphonate</z:chebi> analog known to exert an antiproliferative activity in some human virus-related <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we show that Cidofovir induces a downregulation of the EBV oncoprotein LMP1 associated with a decrease of the antiapoptotic Bcl-2 and an increase of the proapoptotic Bax protein in Raji (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and C15 (NPC) cells </plain></SENT>
<SENT sid="4" pm="."><plain>Using <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell line BL2 B95-8 (BL2 infected with the B95.8 strain of EBV), we addressed the relation between EBV genome expression and modulation of <z:mp ids='MP_0001799'>viral</z:mp> oncoproteins by Cidofovir and/or ionizing radiation (IR) </plain></SENT>
<SENT sid="5" pm="."><plain>Cidofovir was able to significantly reduce LMP1 and EBNA2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression </plain></SENT>
<SENT sid="6" pm="."><plain>This effect was associated with inhibition of proliferation, stimulation of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and decrease of Bcl-2 expression in BL2 B95.8 cells </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, Cidofovir enhanced the radiation-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and the radiosensitivity through the proteolytic cleavage of <z:hpo ids='HP_0011420'>death</z:hpo> effectors caspase-9 and -3, which was specifically induced by combined treatment in EBV-positive cells compared to their negative counterparts </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, the combined treatment in <z:mp ids='MP_0003815'>nude</z:mp> mice led to a complete <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> remission without increasing toxicity in two human EBV-related <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> xenografts (Raji and C15) </plain></SENT>
<SENT sid="9" pm="."><plain>These results provide the basis for a novel anticancer strategy to enhance the therapeutic ratio of IR in EBV-related <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
</text></document>